Lumida
/EBS
⌘K
Emergent BioSolutions Inc

Emergent BioSolutions Inc

EBS
$7.63USD↓-0.78%-0.06 today

MARKET CAP

393.7M

P/E (TTM)

7.6x

FWD P/E

8.0x

DAY RANGE

$7 – $8

52W RANGE

$6
$14

AI Summary

Stalk
TrimMedium

The stock is entrenched in a Stage 4 decline, trading sideways below its major moving averages with persistent lower highs and lower lows. Medium-term bias remains bearish, permitting only sell-side engagement, while short-term conditions lack a clear timing edge. Execution is deferred until price rallies into resistance around the 9/21 EMA cluster or the upper consolidation boundary, where rejection at EMAs can be probed for trade entries.

  • ↑Q4’25 revenue $743M and adj. EBITDA $205M (+12% YoY)
  • ↑Secured $52.7M government contracts; international sales 34% of MCM revenue
  • ↓2026 lacks repeat of $60M intl order, exposing contract volatility
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Emergent BioSolutions Inc. (NYSE: EBS) is a biopharmaceutical company primarily engaged in the development and production of medical countermeasures aimed at addressing public health threats, including those resulting from biological, chemical, radiological, and nuclear agents. The company has established itself as a leading provider of innovative solutions for opioid overdose treatments through its Narcan product, facilitating its pivotal role in combating the ongoing opioid crisis. Emergent is currently navigating through a multi-year transformation, refining its operational strategies, enhancing profitability, and focusing on sustainable growth, which is critical in the context of increasing global demand for its products.

Bull says

  • ↑Q4’25 revenue $743M and adj. EBITDA $205M (+12% YoY)
  • ↑Secured $52.7M government contracts; international sales 34% of MCM revenue
  • ↑Liquidity $367M; $50M share buyback shows strong cash flexibility
  • ↑International markets now 37% of total revenue across Europe/Asia/Middle East
  • ↑Management targeting bolt-on acquisitions to expand Narcan portfolio
  • ↑High earnings yield, manageable leverage, robust liquidity underpin growth

Bear says

  • ↓2026 lacks repeat of $60M intl order, exposing contract volatility
  • ↓Revenue down YoY due to divestitures; growth factor remains weak
  • ↓Intense naloxone competition threatens pricing power and margins
  • ↓International sales volatile from geopolitical risks and order timing
  • ↓Low institutional ownership suggests limited investor confidence
  • ↓Weak growth, poor quality score, low dividend yield risk returns

Investment themes with EBS

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2025 · Mgmt. Guidance

Updated 07-14-2026neutral

Transcript signals

Bull points

  • We delivered on our revenue and adjusted EBITDA targets, while we further improved our cash and liquidity positions.
  • we are reaffirming revenue and adjusted EBITDA guidance for 2025.
  • At the end of the first quarter, we have cash of $149 million on the balance sheet, which includes approximately $36.5 million for the sale of the Bayview site in Baltimore.

Bear points

  • In the first quarter, we managed through two one-time events with Narcan, a third-party distributor selling short-dated generic Naloxone inventory at a reduced price, and states proceeding with caution as it relates to federal funding process for Naloxone.
  • total revenues of $222 million, down versus the prior year as lower Narcan and VAT sales, as well as the divestiture of RSDL and Camden, were partially offset by higher international smallpox sales.
  • First, the full impact of reduced pricing in the public interest space that began to take effect in late 2Q24.
Read full transcript analysis ›